vTv Therapeutics (NASDAQ:VTVT) Releases Earnings Results, Beats Estimates By $0.32 EPS

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.32, Zacks reports. The firm had revenue of $0.02 million for the quarter.

vTv Therapeutics Stock Performance

VTVT stock traded up $0.73 during mid-day trading on Monday, reaching $17.37. 17,896 shares of the stock traded hands, compared to its average volume of 23,006. vTv Therapeutics has a one year low of $12.12 and a one year high of $29.19. The stock has a market capitalization of $55.41 million, a PE ratio of -3.83 and a beta of 1.07. The business has a 50-day moving average price of $16.97 and a two-hundred day moving average price of $15.45.

Analysts Set New Price Targets

Several brokerages recently weighed in on VTVT. Alliance Global Partners started coverage on shares of vTv Therapeutics in a research report on Monday, December 9th. They issued a "buy" rating and a $35.00 price target on the stock. StockNews.com started coverage on shares of vTv Therapeutics in a report on Wednesday, March 19th. They issued a "sell" rating on the stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.